Solara Active Pharma Sciences Limited has informed the Exchange regarding inter alia, to consider and approve the Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2025 along with Limited review Report for the said period.
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Solara Active Pharma Sciences reported Q1 FY26 revenue from operations of Rs. 319.15 Cr, down 12% YoY from Rs. 363.49 Cr but up 15% QoQ from Rs. 273.01 Cr. The company swung to a consolidated profit after tax of Rs. 10.52 Cr from a loss of Rs. 13.46 Cr in the same quarter last year, marking its highest PAT in 12+ quarters. Gross margin expanded sharply by 960 basis points YoY to 54.1%, and EBITDA margin rose to 18.0% (up 639 bps YoY), driven by a higher share of regulated markets (77% of revenue) and cost optimization. Gross debt was reduced from Rs. 776 Cr to Rs. 632.7 Cr using Rs. 112.5 Cr from the rights issue and Rs. 30.8 Cr from operating cash flows. The company also appointed Mr. Rajesh Patro as Chief Risk Officer and noted the ongoing demerger of its CRAMS and Polymers business into a new subsidiary, Synthix Global Pharma Solutions Ltd. Auditor Deloitte Haskins & Sells LLP issued an unmodified limited review conclusion.
The sharp improvement in margins and a return to profit are positive for shareholders, signalling operational turnaround despite a YoY revenue dip. However, the company still carries accumulated losses of Rs. 305 Cr and net current liabilities, with the going concern assumption dependent on the final Rs. 134.99 Cr call from the rights issue, making future capital calls a key risk to monitor.